Earnings Surprises

Biggest EPS beats and misses, ranked by post-earnings price reaction. Free data, no paywall.

Q3 2026 Season
60% beat EPS(vs Q2 2026: 60% beat)Avg surprise: +7.0%Avg reaction: -1.0%22% raised guidance5% lowered464/503 S&P 5004,118 reported

Beats and misses reported Jul 1 – Sep 30, 2026

Biggest EPS Beats25

Ranked by EPS surprise % (highest first). Price reaction = day after report.

#SymbolCompanySectorDateEPS ActualEPS Est.SurprisePrice Reaction
1Corcept Therapeutics IncorporatedHealthcareJul 29, 2026$0.36$0.02+1381%+25.6%
2Cronos Group Inc.HealthcareAug 6, 2026$0.09$0.01+800%+14.0%
Mike Gorenstein, Chairman, President and CEO

Cronos delivered a record second quarter by organically achieving record net revenue, record gross profit and record Adjusted EBITDA, while also reducing our share count. Cronos Israel delivered its tenth consecutive quarter of record net revenue, continuing to secure PEACE NATURALS as the leading cannabis brand in the country. Outside of Israel, our international business also delivered a record net revenue quarter, led by momentum in Germany. In Canada, the Spinach brand continued to gain sign

3Agilon Health, Inc.HealthcareAug 5, 2026$1.04↑ Raised$0.14+622%-8.4%
Tim O’Rourke, Chief Executive Officer

Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence in the strength of our Total Care Model.

4AMN Healthcare Services, Inc.HealthcareAug 6, 2026$0.77— Maintained$0.19+308%+9.8%
Cary Grace, President and Chief Executive Officer

We are very pleased with how the AMN team executed for our healthcare professionals and clients in the second quarter. Our strong performance produced year-over-year revenue growth in our travel nurse, international nurse, allied, schools, and search solutions.

5PTC Therapeutics, Inc.HealthcareJul 30, 2026$0.92$0.24+289%-9.9%
6Oscar Health, Inc.HealthcareAug 6, 2026$1.10↑ Raised$0.40+173%-7.3%
Mark Bertolini, CEO

Oscar delivered record profitability in the first half of the year and we are raising our full-year 2026 guidance. Our superior operating performance and execution against the fundamentals of our strategy are accelerating the individual market.

7ACADIA Pharmaceuticals Inc.HealthcareAug 4, 2026$0.18↑ Raised$0.07+164%+12.5%
Catherine Owen Adams, Chief Executive Officer

Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis.

8Innoviva, Inc.HealthcareAug 5, 2026$1.14— Maintained$0.44+161%+1.2%
Pavel Raifeld, Chief Executive Officer

Innoviva delivered another strong quarter, supported by durable cash generation from our royalty portfolio and continued excellent commercial momentum at IST, which achieved 46% year-over-year net product sales growth, including 26% growth in U.S. sales. We remain on track to achieve at least $150 million in IST U.S. net product sales in 2026, reflecting the differentiation of our marketed critical care and infectious disease portfolio and robust execution.

9Telix Pharmaceuticals LimitedHealthcareAug 19, 2026$0.11$0.04+140%+4.5%
10Centene Corp.HealthcareJul 28, 2026$2.51↑ Raised$1.09+130%-0.3%
Sarah M. London, CEO

Our second quarter results and improved full-year outlook represent meaningful milestones on our path to restoring profitability and increasing shareholder value.

11Omnicell, Inc.HealthcareJul 30, 2026$0.94$0.47+101%-10.4%
12Arcutis Biotherapeutics, Inc.HealthcareAug 5, 2026$0.11↑ Raised$0.06+99.6%-2.5%
Frank Watanabe, President and Chief Executive Officer

Our strong second quarter results reflect the continued strength of the ZORYVE franchise, the leading branded non-steroidal therapy across our three indications. With our investment in expanding our dermatology sales force and initiatives designed to simplify patient access, we are well positioned to drive continued growth and momentum through the second half of 2026.

13BioCryst Pharmaceuticals, Inc.HealthcareAug 5, 2026$0.30$0.15+94.5%+3.1%
14Ascendis Pharma A/SHealthcareAug 13, 2026$3.29$1.71+92.4%-3.6%
15Nutex Health, Inc.HealthcareAug 6, 2026$9.38$4.95+89.5%+3.1%
16Eton Pharmaceuticals, Inc.HealthcareAug 13, 2026$0.35↑ Raised$0.19+84.4%+41.6%
Sean Brynjelsen, CEO

Eton reported another outstanding quarter, delivering 99% year-over-year revenue growth, reflecting the strength of our rare disease portfolio and the exceptional execution of our team.

17LifeStance Health Group, Inc.HealthcareAug 6, 2026$0.06↑ Raised$0.03+82.9%+4.5%
Dave Bourdon, CEO

This was an outstanding second quarter and first half of 2026 for LifeStance, as we delivered quarterly revenue growth of 26%, positive net income of $24 million, and Adjusted EBITDA margins of 15%.

18Surgery Partners, Inc.HealthcareAug 10, 2026$0.10— Maintained$0.06+72.7%+2.7%
Eric Evans, Chief Executive Officer

We are pleased with our progress this quarter, which reflects disciplined execution against our key strategic priorities to support a return to growth and reinforces our conviction in our short stay surgical platform.

19CareDx, IncHealthcareJul 30, 2026$0.37$0.23+59.4%+14.7%
20Neogen CorporationHealthcareJul 30, 2026$0.09$0.06+58.7%+28.1%
21Neurocrine Biosciences, Inc.HealthcareJul 30, 2026$2.85$1.85+54.0%-7.7%
22Baxter International Inc.HealthcareJul 30, 2026$0.56↑ Raised$0.37+52.8%+8.0%
Andrew Hider, President and CEO

Our second-quarter results exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance.

23Bio-Rad Laboratories, Inc.HealthcareAug 4, 2026$2.62$1.75+49.7%+3.9%
24DENTSPLY SIRONA Inc.HealthcareAug 6, 2026$0.52$0.35+49.4%-12.1%
25NeoGenomics, Inc.HealthcareJul 28, 2026$0.05↑ Raised$0.03+48.8%+16.2%
Tony Zook, Chief Executive Officer

Our second quarter results reflect the consistent operating and financial performance investors expect from this team. Revenue growth of 11% year-over-year exceeded our outlook, with NGS revenue growth of 26% reflecting a continued mix shift to more advanced testing modalities. This revenue growth is being coupled with our focus on disciplined margin expansion, as evidenced by adjusted EBITDA increasing by 36%. Looking ahead, I remain confident that we are well positioned to deliver long-term pr

CORT logo1CORTCorcept Therapeutics IncorporatedJul 29, 2026
Mkt Cap$7.3B
EPS Act.$0.36
EPS Est.$0.02
Surprise+1381%
Reaction+25.6%
SectorHealthcare
CRON logo2CRONCronos Group Inc.Aug 6, 2026
Mkt Cap$1.2B
EPS Act.$0.09
EPS Est.$0.01
Surprise+800%
Reaction+14.0%
SectorHealthcare
Mike Gorenstein, Chairman, President and CEO

Cronos delivered a record second quarter by organically achieving record net revenue, record gross profit and record Adjusted EBITDA, while also reducing our share count. Cronos Israel delivered its tenth consecutive quarter of record net revenue, continuing to secure PEACE NATURALS as the leading cannabis brand in the country. Outside of Israel, our international business also delivered a record net revenue quarter, led by momentum in Germany. In Canada, the Spinach brand continued to gain sign

AGL logo3AGLAgilon Health, Inc.Aug 5, 2026
Mkt Cap$1.5B
EPS Act.$1.04
EPS Est.$0.14
Surprise+622%
Reaction-8.4%
SectorHealthcare
Tim O’Rourke, Chief Executive Officer

Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence in the strength of our Total Care Model.

AMN logo4AMNAMN Healthcare Services, Inc.Aug 6, 2026
Mkt Cap$1.5B
EPS Act.$0.77
EPS Est.$0.19
Surprise+308%
Reaction+9.8%
SectorHealthcare
Cary Grace, President and Chief Executive Officer

We are very pleased with how the AMN team executed for our healthcare professionals and clients in the second quarter. Our strong performance produced year-over-year revenue growth in our travel nurse, international nurse, allied, schools, and search solutions.

PTCT logo5PTCTPTC Therapeutics, Inc.Jul 30, 2026
Mkt Cap$5.0B
EPS Act.$0.92
EPS Est.$0.24
Surprise+289%
Reaction-9.9%
SectorHealthcare
OSCR logo6OSCROscar Health, Inc.Aug 6, 2026
Mkt Cap$7.1B
EPS Act.$1.10
EPS Est.$0.40
Surprise+173%
Reaction-7.3%
SectorHealthcare
Mark Bertolini, CEO

Oscar delivered record profitability in the first half of the year and we are raising our full-year 2026 guidance. Our superior operating performance and execution against the fundamentals of our strategy are accelerating the individual market.

ACAD logo7ACADACADIA Pharmaceuticals Inc.Aug 4, 2026
Mkt Cap$3.1B
EPS Act.$0.18
EPS Est.$0.07
Surprise+164%
Reaction+12.5%
SectorHealthcare
Catherine Owen Adams, Chief Executive Officer

Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis.

INVA logo8INVAInnoviva, Inc.Aug 5, 2026
Mkt Cap$1.4B
EPS Act.$1.14
EPS Est.$0.44
Surprise+161%
Reaction+1.2%
SectorHealthcare
Pavel Raifeld, Chief Executive Officer

Innoviva delivered another strong quarter, supported by durable cash generation from our royalty portfolio and continued excellent commercial momentum at IST, which achieved 46% year-over-year net product sales growth, including 26% growth in U.S. sales. We remain on track to achieve at least $150 million in IST U.S. net product sales in 2026, reflecting the differentiation of our marketed critical care and infectious disease portfolio and robust execution.

TLX logo9TLXTelix Pharmaceuticals LimitedAug 19, 2026
Mkt Cap$3.0B
EPS Act.$0.11
EPS Est.$0.04
Surprise+140%
Reaction+4.5%
SectorHealthcare
CNC logo10CNCCentene Corp.Jul 28, 2026
Mkt Cap$33.3B
EPS Act.$2.51
EPS Est.$1.09
Surprise+130%
Reaction-0.3%
SectorHealthcare
Sarah M. London, CEO

Our second quarter results and improved full-year outlook represent meaningful milestones on our path to restoring profitability and increasing shareholder value.

OMCL logo11OMCLOmnicell, Inc.Jul 30, 2026
Mkt Cap$1.6B
EPS Act.$0.94
EPS Est.$0.47
Surprise+101%
Reaction-10.4%
SectorHealthcare
ARQT logo12ARQTArcutis Biotherapeutics, Inc.Aug 5, 2026
Mkt Cap$3.5B
EPS Act.$0.11
EPS Est.$0.06
Surprise+99.6%
Reaction-2.5%
SectorHealthcare
Frank Watanabe, President and Chief Executive Officer

Our strong second quarter results reflect the continued strength of the ZORYVE franchise, the leading branded non-steroidal therapy across our three indications. With our investment in expanding our dermatology sales force and initiatives designed to simplify patient access, we are well positioned to drive continued growth and momentum through the second half of 2026.

BCRX logo13BCRXBioCryst Pharmaceuticals, Inc.Aug 5, 2026
Mkt Cap$1.9B
EPS Act.$0.30
EPS Est.$0.15
Surprise+94.5%
Reaction+3.1%
SectorHealthcare
ASND logo14ASNDAscendis Pharma A/SAug 13, 2026
Mkt Cap$16.8B
EPS Act.$3.29
EPS Est.$1.71
Surprise+92.4%
Reaction-3.6%
SectorHealthcare
NUTX logo15NUTXNutex Health, Inc.Aug 6, 2026
Mkt Cap$1.2B
EPS Act.$9.38
EPS Est.$4.95
Surprise+89.5%
Reaction+3.1%
SectorHealthcare
ETON logo16ETONEton Pharmaceuticals, Inc.Aug 13, 2026
Mkt Cap$1.7B
EPS Act.$0.35
EPS Est.$0.19
Surprise+84.4%
Reaction+41.6%
SectorHealthcare
Sean Brynjelsen, CEO

Eton reported another outstanding quarter, delivering 99% year-over-year revenue growth, reflecting the strength of our rare disease portfolio and the exceptional execution of our team.

LFST logo17LFSTLifeStance Health Group, Inc.Aug 6, 2026
Mkt Cap$5.3B
EPS Act.$0.06
EPS Est.$0.03
Surprise+82.9%
Reaction+4.5%
SectorHealthcare
Dave Bourdon, CEO

This was an outstanding second quarter and first half of 2026 for LifeStance, as we delivered quarterly revenue growth of 26%, positive net income of $24 million, and Adjusted EBITDA margins of 15%.

SGRY logo18SGRYSurgery Partners, Inc.Aug 10, 2026
Mkt Cap$3.5B
EPS Act.$0.10
EPS Est.$0.06
Surprise+72.7%
Reaction+2.7%
SectorHealthcare
Eric Evans, Chief Executive Officer

We are pleased with our progress this quarter, which reflects disciplined execution against our key strategic priorities to support a return to growth and reinforces our conviction in our short stay surgical platform.

CDNA logo19CDNACareDx, IncJul 30, 2026
Mkt Cap$3.8B
EPS Act.$0.37
EPS Est.$0.23
Surprise+59.4%
Reaction+14.7%
SectorHealthcare
NEOG logo20NEOGNeogen CorporationJul 30, 2026
Mkt Cap$2.4B
EPS Act.$0.09
EPS Est.$0.06
Surprise+58.7%
Reaction+28.1%
SectorHealthcare
NBIX logo21NBIXNeurocrine Biosciences, Inc.Jul 30, 2026
Mkt Cap$16.4B
EPS Act.$2.85
EPS Est.$1.85
Surprise+54.0%
Reaction-7.7%
SectorHealthcare
BAX logo22BAXBaxter International Inc.Jul 30, 2026
Mkt Cap$13.5B
EPS Act.$0.56
EPS Est.$0.37
Surprise+52.8%
Reaction+8.0%
SectorHealthcare
Andrew Hider, President and CEO

Our second-quarter results exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance.

BIO logo23BIOBio-Rad Laboratories, Inc.Aug 4, 2026
Mkt Cap$10.0B
EPS Act.$2.62
EPS Est.$1.75
Surprise+49.7%
Reaction+3.9%
SectorHealthcare
XRAY logo24XRAYDENTSPLY SIRONA Inc.Aug 6, 2026
Mkt Cap$1.7B
EPS Act.$0.52
EPS Est.$0.35
Surprise+49.4%
Reaction-12.1%
SectorHealthcare
NEO logo25NEONeoGenomics, Inc.Jul 28, 2026
Mkt Cap$2.0B
EPS Act.$0.05
EPS Est.$0.03
Surprise+48.8%
Reaction+16.2%
SectorHealthcare
Tony Zook, Chief Executive Officer

Our second quarter results reflect the consistent operating and financial performance investors expect from this team. Revenue growth of 11% year-over-year exceeded our outlook, with NGS revenue growth of 26% reflecting a continued mix shift to more advanced testing modalities. This revenue growth is being coupled with our focus on disciplined margin expansion, as evidenced by adjusted EBITDA increasing by 36%. Looking ahead, I remain confident that we are well positioned to deliver long-term pr

Biggest EPS Misses25

Ranked by EPS miss % (worst first). Price reaction = day after report.

#SymbolCompanySectorDateEPS ActualEPS Est.SurprisePrice Reaction
1Ascentage Pharma Group InternationalHealthcareAug 20, 2026-$1.28$0.02-7850%-5.7%
2Xeris Biopharma Holdings, Inc.HealthcareAug 6, 2026-$0.18$0.01-1588%-2.2%
3Caris Life Sciences, Inc.HealthcareAug 5, 2026-$0.00↑ Raised$0.01-139%+24.2%
David Dean Halbert, Founder, Chairman and CEO

This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine.

4Sarepta Therapeutics, Inc.HealthcareAug 5, 2026-$0.05$0.22-123%+2.4%
5TG Therapeutics, Inc.HealthcareAug 3, 2026$0.05$0.31-83.6%-11.3%
6Teva Pharmaceutical Industries LimitedHealthcareJul 29, 2026$0.02$0.08-75.0%+11.8%
7HUTCHMED (China) LimitedHealthcareJul 30, 2026$0.05$0.14-68.3%-2.3%
8AdaptHealth Corp.HealthcareAug 4, 2026$0.06↓ Lowered$0.17-64.5%-40.0%
Suzanne Foster, Chief Executive Officer

In the second quarter, we delivered 15.9% organic growth, with record volume gains across the business. Also, in July we signed a definitive agreement to divest our Diabetes Health business, the most significant step yet in our multi-year effort to focus AdaptHealth on our core Sleep Health, Respiratory Health, and supporting Wellness-at-Home businesses.

9Dr. Reddy's Laboratories LimitedHealthcareJul 21, 2026$0.06$0.09-34.6%-9.2%
10Dr. Reddy's Laboratories LimitedHealthcareJul 22, 2026$0.06$0.09-34.6%-6.0%
11Ardent Health Inc.HealthcareAug 4, 2026$0.12— Maintained$0.18-34.0%+3.8%
Dave Caspers, President and Chief Executive Officer

As I transition to the CEO role, I’m looking forward to building on the momentum of key initiatives launched during my COO tenure as well as Ardent's strong foundation in attractive, growing markets.

12STAAR Surgical CompanyHealthcareAug 12, 2026$0.16— Maintained$0.22-27.7%+1.6%
Tom Frinzi, CEO

I am honored to write to you for the first time as Chief Executive Officer of STAAR and grateful for the opportunity to lead this talented organization.

13Alnylam Pharmaceuticals, Inc.HealthcareJul 30, 2026$1.21$1.63-25.8%-28.3%
14Legend Biotech CorporationHealthcareAug 11, 2026$0.09$0.12-25.0%+5.7%
15Penumbra, Inc.HealthcareJul 30, 2026$0.88$1.16-24.1%+0.3%
16InnovAge Holding Corp.HealthcareSep 8, 2026$0.06↑ Raised$0.07-19.7%+2.6%
Patrick Blair, CEO

Fiscal 2026 was an exceptional year for InnovAge and reflects the significant progress we have made strengthening the company. We enter Fiscal 2027 in a strong position.

17BillionToOne, Inc.HealthcareAug 5, 2026$0.15$0.18-18.2%-35.6%
18TransMedics Group, Inc.HealthcareAug 4, 2026$0.44$0.50-11.2%-6.2%
19Certara, Inc.HealthcareAug 4, 2026$0.08— Maintained$0.09-10.4%-2.1%
Jon Resnick, Chief Executive Officer

This second quarter was about continuing to execute on our commitments. Overall, we are pleased with our ongoing progress transforming Certara into a company we believe can deliver sustainable double-digit growth.

20LeMaitre Vascular, Inc.HealthcareAug 4, 2026$0.74— Maintained$0.81-8.3%-23.8%
George LeMaitre, Chairman/CEO

Our focus on the Artegraft international launch paid off in Q2. The product is now approved in 56 countries, accounting for 21% of sales. So our largest product is now our fastest-growing product. To underpin the Artegraft launch and pave the way for RFA, we continue to build our sales force, go direct in new countries and we’re now undertaking six international warehouse expansions. $376m of cash provides strategic optionality.

21U.S. Physical Therapy, Inc.HealthcareAug 5, 2026$0.75$0.81-7.9%+0.8%
22Jazz Pharmaceuticals plcHealthcareAug 3, 2026$5.71↑ Raised$6.18-7.6%+3.5%
Renee Gala, President and CEO

Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance.

23Grifols, S.A.HealthcareJul 28, 2026$0.25$0.27-7.0%+5.2%
24Doximity, Inc.HealthcareAug 6, 2026$0.29— Maintained$0.30-4.3%+26.7%
Jeff Tangney, co-founder and CEO

We're proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement.

25Hinge Health, Inc.HealthcareAug 4, 2026$0.59↑ Raised$0.61-4.1%+1.7%
Daniel Perez, Co-Founder and CEO

We delivered another strong quarter ahead of expectations, generating $213 million in revenue with 53% year-over-year growth, while more than tripling free cash flow from a year ago.

AAPG logo1AAPGAscentage Pharma Group InternationalAug 20, 2026
Mkt Cap$1.2B
EPS Act.-$1.28
EPS Est.$0.02
Surprise-7850%
Reaction-5.7%
SectorHealthcare
XERS logo2XERSXeris Biopharma Holdings, Inc.Aug 6, 2026
Mkt Cap$2.9B
EPS Act.-$0.18
EPS Est.$0.01
Surprise-1588%
Reaction-2.2%
SectorHealthcare
CAI logo3CAICaris Life Sciences, Inc.Aug 5, 2026
Mkt Cap$5.5B
EPS Act.-$0.00
EPS Est.$0.01
Surprise-139%
Reaction+24.2%
SectorHealthcare
David Dean Halbert, Founder, Chairman and CEO

This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine.

SRPT logo4SRPTSarepta Therapeutics, Inc.Aug 5, 2026
Mkt Cap$1.5B
EPS Act.-$0.05
EPS Est.$0.22
Surprise-123%
Reaction+2.4%
SectorHealthcare
TGTX logo5TGTXTG Therapeutics, Inc.Aug 3, 2026
Mkt Cap$10.1B
EPS Act.$0.05
EPS Est.$0.31
Surprise-83.6%
Reaction-11.3%
SectorHealthcare
TEVA logo6TEVATeva Pharmaceutical Industries LimitedJul 29, 2026
Mkt Cap$50.0B
EPS Act.$0.02
EPS Est.$0.08
Surprise-75.0%
Reaction+11.8%
SectorHealthcare
HCM logo7HCMHUTCHMED (China) LimitedJul 30, 2026
Mkt Cap$2.4B
EPS Act.$0.05
EPS Est.$0.14
Surprise-68.3%
Reaction-2.3%
SectorHealthcare
AHCO logo8AHCOAdaptHealth Corp.Aug 4, 2026
Mkt Cap$1.0B
EPS Act.$0.06
EPS Est.$0.17
Surprise-64.5%
Reaction-40.0%
SectorHealthcare
Suzanne Foster, Chief Executive Officer

In the second quarter, we delivered 15.9% organic growth, with record volume gains across the business. Also, in July we signed a definitive agreement to divest our Diabetes Health business, the most significant step yet in our multi-year effort to focus AdaptHealth on our core Sleep Health, Respiratory Health, and supporting Wellness-at-Home businesses.

RDY logo9RDYDr. Reddy's Laboratories LimitedJul 21, 2026
Mkt Cap$12.5B
EPS Act.$0.06
EPS Est.$0.09
Surprise-34.6%
Reaction-9.2%
SectorHealthcare
RDY logo10RDYDr. Reddy's Laboratories LimitedJul 22, 2026
Mkt Cap$12.5B
EPS Act.$0.06
EPS Est.$0.09
Surprise-34.6%
Reaction-6.0%
SectorHealthcare
ARDT logo11ARDTArdent Health Inc.Aug 4, 2026
Mkt Cap$2.1B
EPS Act.$0.12
EPS Est.$0.18
Surprise-34.0%
Reaction+3.8%
SectorHealthcare
Dave Caspers, President and Chief Executive Officer

As I transition to the CEO role, I’m looking forward to building on the momentum of key initiatives launched during my COO tenure as well as Ardent's strong foundation in attractive, growing markets.

STAA logo12STAASTAAR Surgical CompanyAug 12, 2026
Mkt Cap$1.3B
EPS Act.$0.16
EPS Est.$0.22
Surprise-27.7%
Reaction+1.6%
SectorHealthcare
Tom Frinzi, CEO

I am honored to write to you for the first time as Chief Executive Officer of STAAR and grateful for the opportunity to lead this talented organization.

ALNY logo13ALNYAlnylam Pharmaceuticals, Inc.Jul 30, 2026
Mkt Cap$19.9B
EPS Act.$1.21
EPS Est.$1.63
Surprise-25.8%
Reaction-28.3%
SectorHealthcare
LEGN logo14LEGNLegend Biotech CorporationAug 11, 2026
Mkt Cap$3.0B
EPS Act.$0.09
EPS Est.$0.12
Surprise-25.0%
Reaction+5.7%
SectorHealthcare
PEN logo15PENPenumbra, Inc.Jul 30, 2026
Mkt Cap$12.6B
EPS Act.$0.88
EPS Est.$1.16
Surprise-24.1%
Reaction+0.3%
SectorHealthcare
INNV logo16INNVInnovAge Holding Corp.Sep 8, 2026
Mkt Cap$1.2B
EPS Act.$0.06
EPS Est.$0.07
Surprise-19.7%
Reaction+2.6%
SectorHealthcare
Patrick Blair, CEO

Fiscal 2026 was an exceptional year for InnovAge and reflects the significant progress we have made strengthening the company. We enter Fiscal 2027 in a strong position.

BLLN logo17BLLNBillionToOne, Inc.Aug 5, 2026
Mkt Cap$4.2B
EPS Act.$0.15
EPS Est.$0.18
Surprise-18.2%
Reaction-35.6%
SectorHealthcare
TMDX logo18TMDXTransMedics Group, Inc.Aug 4, 2026
Mkt Cap$3.3B
EPS Act.$0.44
EPS Est.$0.50
Surprise-11.2%
Reaction-6.2%
SectorHealthcare
CERT logo19CERTCertara, Inc.Aug 4, 2026
Mkt Cap$1.7B
EPS Act.$0.08
EPS Est.$0.09
Surprise-10.4%
Reaction-2.1%
SectorHealthcare
Jon Resnick, Chief Executive Officer

This second quarter was about continuing to execute on our commitments. Overall, we are pleased with our ongoing progress transforming Certara into a company we believe can deliver sustainable double-digit growth.

LMAT logo20LMATLeMaitre Vascular, Inc.Aug 4, 2026
Mkt Cap$1.7B
EPS Act.$0.74
EPS Est.$0.81
Surprise-8.3%
Reaction-23.8%
SectorHealthcare
George LeMaitre, Chairman/CEO

Our focus on the Artegraft international launch paid off in Q2. The product is now approved in 56 countries, accounting for 21% of sales. So our largest product is now our fastest-growing product. To underpin the Artegraft launch and pave the way for RFA, we continue to build our sales force, go direct in new countries and we’re now undertaking six international warehouse expansions. $376m of cash provides strategic optionality.

USPH logo21USPHU.S. Physical Therapy, Inc.Aug 5, 2026
Mkt Cap$1.5B
EPS Act.$0.75
EPS Est.$0.81
Surprise-7.9%
Reaction+0.8%
SectorHealthcare
JAZZ logo22JAZZJazz Pharmaceuticals plcAug 3, 2026
Mkt Cap$15.6B
EPS Act.$5.71
EPS Est.$6.18
Surprise-7.6%
Reaction+3.5%
SectorHealthcare
Renee Gala, President and CEO

Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance.

GRFS logo23GRFSGrifols, S.A.Jul 28, 2026
Mkt Cap$7.2B
EPS Act.$0.25
EPS Est.$0.27
Surprise-7.0%
Reaction+5.2%
SectorHealthcare
DOCS logo24DOCSDoximity, Inc.Aug 6, 2026
Mkt Cap$5.7B
EPS Act.$0.29
EPS Est.$0.30
Surprise-4.3%
Reaction+26.7%
SectorHealthcare
Jeff Tangney, co-founder and CEO

We're proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement.

HNGE logo25HNGEHinge Health, Inc.Aug 4, 2026
Mkt Cap$8.9B
EPS Act.$0.59
EPS Est.$0.61
Surprise-4.1%
Reaction+1.7%
SectorHealthcare
Daniel Perez, Co-Founder and CEO

We delivered another strong quarter ahead of expectations, generating $213 million in revenue with 53% year-over-year growth, while more than tripling free cash flow from a year ago.